The Arizona spinout is searching for non-opioid painkillers that target sections of the nerve cell membrane thought responsible for pain disorders.
Regulonix, a US-based non-opioid painkillers developer spun out from University of Arizona (UA), has licensed a set of drug candidates from the institution.
The spinout is working on technology to target a transmission mechanism in the nerve cell membrane – the Nav1.7 sodium channel – that is thought to be responsible for chronic pain disorders.
Other sodium channels would remain relatively unaffected to avoid associated side effects.
Regulonix has received $300,000 in grant funding from the US government’s Department of…
